Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trials (PDQ®)

Genetic and Etiologic Multidisciplinary Study of Familial Testicular Cancer

Alternate Title
Basic Trial Information
Entry Criteria
Expected Enrollment
Published Results
Trial Contact Information
Related Information
Registry Information

Alternate Title

Study of Individuals and Families at High Risk for Testicular Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedGenetics, Natural history/Epidemiology, Tissue collection/RepositoryActive12 and overNCINCI-02-C-0178

Special Category: NIH Clinical Center trial, NCI Web site featured trial


  1. Identify new families with familial testicular germ cell tumors (TGCT).
  2. Determine the clinical features of familial TGCT.
  3. Determine the underlying genetic mechanism for susceptibility to familial TGCT.
  4. Determine the various parameters related to psychosocial and behavioral issues resulting from being a member of a family at increased risk of TGCT.

Entry Criteria

Disease Characteristics:

  • Members of families with familial testicular germ cell tumor (TGCT) defined by 1 of the following:
    • At least 2 documented cases of germ cell tumor (at least 1 of which is testicular in origin) in blood relatives
    • A single family member with bilateral testicular cancer
    • Men with a history of TGCT who are one in a set of identical siblings
      • The unaffected identical sibling must also agree to participate in the study

  • TGCT case defined as histologically confirmed germ cell-derived tumor arising in the testis
    • Seminoma
    • Germinoma
    • Embryonal carcinoma
    • Endodermal sinus (yolk sac) tumor
    • Gonadoblastoma
    • Choriocarcinoma
    • Teratoma
    • Mixed germ cell tumor
    • Extragonadal germ cell tumors allowed

  • Eligible individuals from participating families include:
    • All TGCT patients
    • All GCT patients, including those with ovarian or extragonadal germ cell tumors
    • All first-degree relatives of each TGCT patient
    • Spouse of every TGCT patient if the spouse and patient had children who are participating in the study
    • Any other blood relative who genetically links 2 patients
    • Any blood relative with cancer other than TGCT

  • Families of deceased TGCT patients are eligible only if the surviving spouse and children are willing to participate in the study

  • Critical informative family members must be willing to participate

Prior/Concurrent Therapy:

Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified

Patient Characteristics:


  • 12 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified

Expected Enrollment


Approximately 750 participants will be accrued for this study within 5 years.


Primary Outcome(s)

Ascertain new families with familial testicular germ cell tumors (TGCT)
Characterize the clinical features (phenotype) of familial TGCT with data acquired through medical history, physical examination, dysmorphology examination, imaging studies, and laboratory samples
Underlying genetic mechanism for susceptibility to TGCT in families by genome-wide linkage analysis, dense genotyping marker panels targeted at candidate regions, positional cloning, candidate gene testing through collaboration with the International Testicular Cancer Linkage Consortium
Evaluate various parameters related to psychosocial and behavioral issues resulting from being a member of a family at increased risk of TGCT by assessing genetic knowledge, interest in genetic testing, reproductive decision-making, quality of life, screening behavior related to testicular and other cancers, measures of cancer worry, and psychosocial distress
Create a repository of biological samples from members of high-risk families for subsequent etiologic and translational research by collection of serum, plasma, whole blood, DNA, semen, and tumor tissue


This is a two-part study.

  • Part 1 (genetic study): Participants contribute DNA for analysis. Participants also complete personal and family medical history, risk factor exposure, and psychosocial and behavioral questionnaires.

  • Part 2 (etiology study): Participants undergo clinical evaluation including physical exam, blood tests, and imaging studies (CT scan or MRI and ultrasound) of the chest, abdomen, pelvis, and gonads.

A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.

Participants do not receive the results of the genetic analysis, which is aimed at finding new testicular cancer susceptibility genes. The results do not influence the type or duration of treatment. Genetic testing for mutations in known genes cannot be performed, as none of these genes have yet been identified.

Participants are followed annually for 5 years.

Published Results

Mai PL, Korde L, Kramer J, et al.: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Reports 1: 9, 2007.[PUBMED Abstract]

Mueller CM, Korde L, Katki HA, et al.: Constitutional cytogenetic analysis in men with hereditary testicular germ cell tumor: no evidence of disease-related abnormalities. Cancer Epidemiol Biomarkers Prev 16 (12): 2791-4, 2007.[PUBMED Abstract]

Peters JA, Vadaparampil ST, Kramer J, et al.: Familial testicular cancer: interest in genetic testing among high-risk family members. Genet Med 8 (12): 760-70, 2006.[PUBMED Abstract]

Rapley EA, Crockford GP, Easton DF, et al.: Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS 111 (1): 128-33; discussion 33-5, 2003.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

Christian Kratz, Principal investigator
Ph: 301-402-2183
Larissa Korde, MD, MPH, Protocol chair
Ph: 301-402-2183

Trial Sites

 Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
 CGB Family Studies Research Nurse
Ph: 800-518-8474

Related Information

Web site for additional information
Featured trial article

Registry Information
Official Title Multidisciplinary Etiologic Study Of Familial Testicular Cancer
Trial Start Date 2002-05-06
Trial Completion Date 2015-12-31 (estimated)
Registered in NCT00039598
Date Submitted to PDQ 2002-05-06
Information Last Verified 2009-06-07

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top